Swift B, Taneri B, Becker CM, Basarir H, Naci H, Missmer SA, Zondervan KT, Rahmioglu N. Prevalence, diagnostic delay and economic burden of endometriosis and its impact on quality of life: results from an Eastern Mediterranean population. Eur J Public Health. 2024 Apr 3;34(2):244-52. doi: 10.1093/eurpub/ckad216
Castan-Abad MT, Montserrat-Capdevila J, Godoy P, Marsal JR, Ortega M, Alseda M, Barbe F. Diabetes as a risk factor for severe exacerbation and death in patients with COPD: a prospective cohort study. Eur J Public Health. 2020 Aug 1;30(4):822-7. doi: 10.1093/eurpub/ckz219
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Curto A, De Nazelle A, Donaire-Gonzalez D, Cole-Hunter T, Garcia-Aymerich J, Martinez D, Anaya E, Rodríguez D, Jerrett M, Nieuwenhuijsen MJ. Private and public modes of bicycle commuting: a perspective on attitude and perception. Eur J Public Health. 2016 Aug;26(4):717-23. doi: 10.1093/eurpub/ckv235
Sawant RV, Goyal RK, Rajan SS, Essien EJ, Patel HK, Sansgiry SS. Factors associated with intention to engage in self-protective behavior: the case of over-the-counter acetaminophen products. Res Social Adm Pharm. 2016 Mar;12(2):327-35. doi: 10.1016/j.sapharm.2015.06.005
Nussbaumer B, Kaminski-Hartenthaler A, Forneris CA, Winkler D, Sonis JH, Gaynes BN, Wipplinger J, Morgan C, Greenblatt A, Lux LJ, Van Noord MG. Prevention of seasonal affective disorder-systematic review and meta-analyses. Poster presented at the 8th European Public Health Conference; October 14, 2015. Milan, Italy. [abstract] Eur J Public Health. 2015 Oct; 25(suppl_3):ckv172-08. doi: 10.1093/eurpub/ckv172.084
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Nagar S, Mehta S, Bhatara V, Aparasu R. Health care consequences of black-box warnings for antidepressants in the United States and Canada. Res Social Adm Pharm. 2010 Mar;6(1):78-84.